Acquired Hemophilia Treatment Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The acromegaly market size has grown rapidly in recent years. It will grow from $2.15 billion in 2024 to $2.57 billion in 2025 at a compound annual growth rate (CAGR) of 19.6%. The growth in the historic period can be attributed to increasing prevalence of acromegaly therapeutics, growing awareness about acromegaly, government initiatives, demand for effective treatments.

The acromegaly market size is expected to see rapid growth in the next few years. It will grow to $4.92 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to investments in research and development activities for acromegaly treatments, growing number of screening programs, rising healthcare spending, increasing demand for minimally invasive treatment options. Major trends in the forecast period include innovative treatments for acromegaly, development of targeted therapies for acromegaly, strong pipeline of drugs, advancements in treatment options, advanced personalized medicine.

The rising incidence of hormonal diseases, such as diabetes, is expected to drive growth in the acromegaly market. Hormonal diseases, or endocrine disorders, arise from dysfunctions within the endocrine system, with diabetes being among the most common and impactful. Acromegaly and other endocrine disorders can occur due to the excessive production of certain hormones, like growth hormone or cortisol. Additionally, elevated growth hormone levels can affect insulin production, leading to insulin resistance or type 2 diabetes mellitus in approximately 50% of individuals with acromegaly. For example, in March 2024, data from the UK’s Office for Health Improvement and Disparities revealed that between March 2022 and March 2023, the percentage of type 1 diabetes patients completing all eight recommended care processes increased by 22%, and for type 2 diabetes, by 21%. The proportion achieving target HbA1c levels reached 37.9%, the highest ever reported by the National Diabetes Audit (NDA). Consequently, the growing prevalence of hormonal diseases is a key factor propelling the acromegaly market forward.

The escalating prevalence of genetic abnormalities is poised to be a key driver for the future expansion of the acromegaly market. Genetic abnormalities, often known as genetic defects or genetic disorders, encompass alterations or mutations that manifest in the DNA sequence of an individual's genes and can lead to atypical features, functions, or characteristics. Acromegaly, a condition characterized by the overproduction of growth hormone (GH) by the pituitary gland, is frequently associated with noncancerous adenomas, which can occur sporadically or be linked to specific genetic abnormalities. For instance, as of February 2022, data from the World Health Organization (WHO), a Switzerland-based intergovernmental organization, indicated that congenital abnormalities contribute to the mortality of 240,000 newborns within the first 28 days of life annually. Additionally, an extra 170,000 children aged between 1 month and 5 years lose their lives due to congenital abnormalities, encompassing conditions like heart defects, neural tube defects, and Down syndrome. Consequently, the rising incidence of genetic abnormalities is poised to propel the acromegaly market forward.

Leading companies in the acromegaly market are prioritizing the development of innovative products and solutions, such as generic lanreotide, to expand treatment options and improve patient outcomes. Generic lanreotide is an unbranded version of the medication used to treat acromegaly and certain neuroendocrine tumors. As a somatostatin analogue, it helps reduce growth hormone secretion, making effective treatment more accessible for patients. For example, in October 2024, Teva Pharmaceutical Industries Ltd., an Israel-based company specializing in generic drugs, launched the first generic version of Sandostatin LAR Depot in the U.S. This injectable suspension, octreotide acetate, is indicated for treating acromegaly and severe diarrhea linked to carcinoid syndrome, providing essential therapy access to patients in need.

In July 2024, AstraZeneca plc, a UK-based multinational pharmaceutical and biotechnology company, acquired Amolyt Pharma for $1.05 billion. This acquisition enhances AstraZeneca's pipeline in rare disease treatments, particularly in endocrine and metabolic disorders, as Amolyt's innovative therapies complement the company's commitment to advancing patient care and addressing unmet medical needs. Amolyt Pharma, a France-based clinical-stage biopharmaceutical company, specializes in developing treatments for rare endocrine diseases, including eneboparatide for hypoparathyroidism and AZP-3813, a peptide antagonist for acromegaly.

Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc, Strongbridge Biopharma PLC, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

North America was the largest region in the acromegaly market in 2024. The regions covered in acromegaly report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the acromegaly market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The acromegaly market consists of revenues earned by entities by providing hormone replacement therapy, pituitary radiotherapy and lifestyle modifications. The market value includes the value of related goods sold by the service provider or included within the service offering. The acromegaly market also includes sales of octreotide, lanreotide and somavert. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Acromegaly is an infrequent hormonal disorder stemming from the excessive production of growth hormone by the pituitary gland, a small structure situated at the base of the brain. This surplus of growth hormone triggers the enlargement and thickening of bones and tissues, predominantly affecting areas such as the hands, feet, and face.

The primary classifications of acromegaly encompass ectopic acromegaly and acromegaly due to growth hormone. Ectopic acromegaly is a rare medical condition characterized by the overproduction of growth hormone (GH) originating from a source outside the pituitary gland. The diagnostic methods employed include GH and IGF-I measurement, growth hormone suppression tests, imaging, and various others, which can be administered through diverse routes, including oral, parenteral, and others. Treatment options are available, ranging from medications, somatostatin analogues, dopamine agonists, and growth hormone antagonists to surgical procedures, radiation therapy, and other approaches. These treatments find application across various end users, including hospitals, specialty clinics, homecare settings, and others.

The acromegaly market research report is one of a series of new reports that provides acromegaly market statistics, including acromegaly industry global market size, regional shares, competitors with an acromegaly market share, detailed acromegaly market segments, market trends and opportunities and any further data you may need to thrive in the acromegaly industry. This acromegaly market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.